<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749422</url>
  </required_header>
  <id_info>
    <org_study_id>15-00732</org_study_id>
    <nct_id>NCT02749422</nct_id>
  </id_info>
  <brief_title>fMRI Guided TMS Enhancement of Associative Memory Networks</brief_title>
  <official_title>A Randomized Controlled Pilot Study of TMS Enhancement of Associative Memory Networks in Healthy Subjects and Epilepsy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blinded, controlled phase 1 study to demonstrate feasibility and
      explore the neurophysiologic and clinical effects of repetitive transcranial magnetic
      stimulation (TMS) interventions in epilepsy patients and healthy controls. The inclusion of a
      control group will be used to see whether epilepsy patients, who suffer from a higher degree
      of comorbid memory difficulty presumably from entorhinal-hippocampal dysfunction, can benefit
      from a TMS intervention can benefit as much as a healthy matched population. Investigators
      will also be looking at functional connectivity between the hippocampus and cortical regions
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in score on cognitive testing face recognition task</measure>
    <time_frame>Day 1, Day 7; Week 10; Week 12; Week 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fMRI Connectivity</measure>
    <time_frame>Day 1, Day 7; Week 10; Week 12; Week 15</time_frame>
    <description>Changes in hippocampal-cortical functional connectivity between baseline assessment and resting state fMRI assessment following TMS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Temporal Lobe Epilepsy Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MagStim RapidStim2</intervention_name>
    <description>Repetitive transcranial magnetic stimulation (TMS)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Temporal Lobe Epilepsy Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fluent in English

          -  Right-handed

          -  Score at least 26 out of 30 on the Montreal Cognitive Assessment (MOCA). Healthy
             subjects will be matched to age, handedness, and education compared to epilepsy
             subjects.

          -  Must be able to provide informed consent.

        Exclusion Criteria:

          -  Any history of a neurological disorder

          -  Chronic or progressive medical condition

          -  Any history of severe traumatic brain injury or skull defect

          -  Metal or devices in the head, including neurostimulators of metal foreign bodies

          -  Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.

          -  Any other ferromagnetic substance in the body (including tattoos, dental prosthetics,
             etc).

          -  Taking a medication which may lower the seizure threshold within the 4 weeks prior to
             the start of the study, including use of neuroleptic (esp. clozapine), antibiotic
             (penicillin, cephalosporins), and bronchodilating medications.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anli Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive dysfunction</keyword>
  <keyword>memory loss</keyword>
  <keyword>non-invasive transcranial magnetic stimulation (TMS)</keyword>
  <keyword>rTMS</keyword>
  <keyword>Magstim Rapid2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

